Eidos Therapeutics, Inc. (EIDX) financial statements (2021 and earlier)

Company profile

Business Address 101 MONTGOMERY STREET, SUITE 2550
SAN FRANCISCO, CA 94104
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments147175197191166131147
Cash and cash equivalents147175197191166131147
Receivables0000000
Other undisclosed current assets6445542
Total current assets:154179201196171136149
Noncurrent Assets
Operating lease, right-of-use asset44444  
Property, plant and equipment1111100
Other noncurrent assets3333233
Other undisclosed noncurrent assets     11
Total noncurrent assets:8888844
TOTAL ASSETS:161187209204179139153
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6955634
Accounts payable2243423
Accrued liabilities1510100
Employee-related liabilities3112111
Debt  110  
Deferred compensation liability0000000
Due to related parties0000000
Other undisclosed current liabilities7664333
Total current liabilities:141512101068
Noncurrent Liabilities
Long-term debt and lease obligation212121215  
Long-term debt, excluding current maturities17171616   
Operating lease, liability44455  
Liabilities, other than long-term debt4111000
Other liabilities3000000
Derivative instruments and hedges, liabilities1111   
Other undisclosed noncurrent liabilities     11
Total noncurrent liabilities:25222222511
Total liabilities:383734321579
Stockholders' equity
Stockholders' equity attributable to parent123149175171164132144
Common stock0000000
Additional paid in capital308304301274248223221
Accumulated deficit(185)(155)(126)(103)(84)(91)(77)
Total stockholders' equity:123149175171164132144
TOTAL LIABILITIES AND EQUITY:161187209204179139153

Income statement (P&L) ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Revenues0   27  
Cost of revenue
(Cost of Goods and Services Sold)
    (3)  
Gross profit:0   24  
Operating expenses(30)(28)(23)(19)(18)(15)(13)
Other undisclosed operating income 000   
Operating income (loss):(29)(28)(23)(19)6(15)(13)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
(0)(0)11111
Interest and debt expense(1)(1)(1)    
Other undisclosed loss from continuing operations before equity method investments, income taxes   (0)   
Net income (loss) available to common stockholders, diluted:(30)(29)(23)(19)7(14)(12)

Comprehensive Income ($ in millions)

9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
Net income (loss):(30)(29)(23)(19)7(14)(12)
Comprehensive income (loss), net of tax, attributable to parent:(30)(29)(23)(19)7(14)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: